Appropriate patient selection and overall survival after transarterial radioembolization in colorectal adenocarcinoma liver metastases

² Department of Radiological Sciences, Division of Vascular and Interventional Radiology, University of California Irvine, Orange, California, United States of America

³ Department of Radiation Oncology Orange, University of California Irvine, California, United States of America

⁴ Department of Surgery, Division of Hepatobiliary Surgery, University of California Irvine, Orange, California, United States of America

JCTR 2023, 9(5), 322–326; https://doi.org/10.18053/jctres.09.202305.23-00066

Submitted: 13 May 2023 | Revised: 12 July 2023 | Accepted: 12 July 2023 | Published: 23 September 2023

© 2023 by the Author(s). This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )

Download PDF

Cite

XML

Abstract

Background and aim: The objective of this study was to describe the overall survival (OS) with transarterial radioembolization (TARE) for patients with colorectal adenocarcinoma liver metastases (CRLM) treated at an academic center with a dedicated multidisciplinary liver tumor board (MTB).

Methods: Single institution retrospective study of consecutive patients with CRLM undergoing TARE with mainly Y90 resin spheres between 01/2016-07/2020.

Results: Fifty-five patients were included. Median age was 60 years (range 36-84), 61.8% were female, ECOG 0-1= 90.9%. The median time from diagnosis to first TARE was 16.4 months (1.7-95.6) and 36.4% were treated within the first 12 months of diagnosis. With a median follow-up of at least two years, the median OS from the date of diagnosis and first TARE was 43.2 months (29.5-68.7) and 16.7 months (9.9-35.2), respectively.

Conclusions: The observed OS in this cohort compares favorably to OS reported in contemporary phase 3 trials and might indicate a benefit of TARE with appropriate patient selection at experienced centers with dedicated MTB.

Relevance for Patients: Oncologists treating patients with CRLM should consider referral to a tertiary treatment center with a multidisciplinary team and TARE treatment expertise.

Keywords

Colorectal liver metastases

Yttrium-90 spheres

Transarterial radioembolization

Survival

Conflict of interest

FD reports honoraria from Astrazeneca, Eisai, Exelixis, Servier, Sirtex, and Ipsen. NAJ has received research funding to the institution from Sirtex and Theraspheres. All other authors declare no disclosures.

References

[1] Benson AB, Venook AP, Al-Hawary MM, Arain MA, Chen YJ, Ciombor KK, et al. Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2021;19:329-59.

[2] Del Rosario MP, Abi-Jaoudeh N, Cho MT, Jutric Z, Dayyani F. Yttrium-90 Internal Radiation Therapy as Part of the Multimodality Treatment of Metastatic Colorectal Carcinoma. Onco 2021;1:207-18.

[3] Mulcahy MF, Mahvash A, Pracht M, Montazeri AH, Bandula S, Martin 2nd RC, et al. Radioembolization with Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial. J Clin Oncol 2021;39:3897-907.

[4] Van Hazel GA, Heinemann V, Sharma NK, Findlay MP, Ricke J, Peeters M, et al. SIRFLOX: Randomized Phase III Trial Comparing First-line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients with Metastatic Colorectal Cancer. J Clin Oncol 2016,34:1723-31.

[5] Riaz A, Lewandowski RJ, Kulik LM, Mulcahy MF, Sato KT, Ryu RK, et al. Complications Following Radioembolization with Yttrium-90 Microspheres: A Comprehensive Literature Review. J Vasc Interv Radiol 2009;20:1121-30.

[6] Kennedy AS, Coldwell D, Nutting C, Murthy R, Wertman DE Jr., Loehr SP, et al. Resin 90Y-Microsphere Brachytherapy for Unresectable Colorectal Liver Metastases: Modern USA Experience. Int J Radiat Oncol Biol Phys 2006;65:412-25.

[7] Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Nemcek AA Jr., Kulik L, et al. Radioembolization with 90Y Microspheres: Angiographic and Technical Considerations. Cardiovasc Intervent Radiol 2007;30:571-92.

[8] Salem R, Lewandowski RJ, Sato KT, Atassi B, Ryu RK, Ibrahim S, et al. Technical Aspects of Radioembolization with 90Y Microspheres. Tech Vasc Interv Radiol 2007;10:12-29.

[9] Riaz A, Gates VL, Atassi B, Lewandowski RJ, Mulcahy MF, Ryu RK, et al. Radiation Segmentectomy: A Novel Approach to Increase Safety and Efficacy of Radioembolization. Int J Radiat Oncol Biol Phys 2011;79:163-71.

[10] Padia SA, Kwan SW, Roudsari B, Monsky WL, Coveler A, Harris WP. Superselective Yttrium-90 Radioembolization for Hepatocellular Carcinoma Yields High Response Rates with Minimal Toxicity. J Vasc Interv Radiol 2014;25:1067-73.

[11] Lewandowski RJ, Gabr A, Abouchaleh N, Ali R, Al Asadi A, Mora RA, et al. Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma. Radiology 2018;287:1050-8.

[12] Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and Outcomes Following Hepatic Resection, Radiofrequency Ablation, and Combined Resection/Ablation for Colorectal Liver Metastases. Ann Surg 2004;239:818-25.

[13] Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, et al. Effect of First-Line Chemotherapy Combined with Cetuximab or Bevacizumab on Overall Survival in Patients with KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA 2017;317:2392-401.

Previous article in this issue

Next article in this issue

Journal of Clinical and Translational Research, Electronic ISSN: 2424-810X Print ISSN: 2382-6533, Published by AccScience Publishing